Victoria Fernandez

Barcelona, CT, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Refining Treatment Monitoring in Patients With Relapsing Multiple Sclerosis Based on Changes on Neurofilament Light Chain Z-Scores.

Refining Treatment Monitoring in Patients With Relapsing Multiple Sclerosis Based on Changes on Neurofilament Light Chain Z-Scores.

Journal: Neurology

Published: August 20, 2026

Cerebrospinal 14-3-3 Protein Levels as a Neuroaxonal Biomarker in Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder.

Cerebrospinal 14-3-3 Protein Levels as a Neuroaxonal Biomarker in Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: June 30, 2025

Performance of treatment response scoring systems among patients with multiple sclerosis treated with high-efficacy therapies.

Performance of treatment response scoring systems among patients with multiple sclerosis treated with high-efficacy therapies.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: February 10, 2025

Uncovering alternative diagnoses in patients with clinical syndromes suggestive of multiple sclerosis: A transversal study from the prospective Barcelona CIS cohort.

Uncovering alternative diagnoses in patients with clinical syndromes suggestive of multiple sclerosis: A transversal study from the prospective Barcelona CIS cohort.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: February 05, 2025

Age-Related Disability Outcomes After a First Demyelinating Event.

Age-Related Disability Outcomes After a First Demyelinating Event.

Journal: Neurology

Published: February 04, 2025

Complement Activation Profiles Predict Clinical Outcomes in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.

Complement Activation Profiles Predict Clinical Outcomes in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: December 11, 2024

The Use of Motor-Evoked Potentials in Clinical Trials in Multiple Sclerosis.

The Use of Motor-Evoked Potentials in Clinical Trials in Multiple Sclerosis.

Journal: Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society

Published: May 07, 2021

Developmental Dynamic Dysphasia: Are Bilateral Brain Abnormalities a Signature of Inefficient Neural Plasticity?

Developmental Dynamic Dysphasia: Are Bilateral Brain Abnormalities a Signature of Inefficient Neural Plasticity?

Journal: Frontiers in human neuroscience

Published: June 12, 2019

Adipose-derived mesenchymal stem cells (AdMSC) for the treatment of secondary-progressive multiple sclerosis: A triple blinded, placebo controlled, randomized phase I/II safety and feasibility study.

Adipose-derived mesenchymal stem cells (AdMSC) for the treatment of secondary-progressive multiple sclerosis: A triple blinded, placebo controlled, randomized phase I/II safety and feasibility study.

Journal: PloS one

Published: June 28, 2017

Evoked potentials are of little use in the diagnosis or monitoring of MS: no.

Evoked potentials are of little use in the diagnosis or monitoring of MS: no.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: November 27, 2013

Recommendations for the clinical use of motor evoked potentials in multiple sclerosis

Recommendations for the clinical use of motor evoked potentials in multiple sclerosis

Journal: Neurologia (Barcelona, Spain)

Published: July 12, 2012

Showing 1-11 of 11

Last Updated: 09/26/2026